Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Arizona.
Press releases published on September 22, 2025
HonorHealth 1st in Arizona and the Southwest to offer new leadless cardiac resynchronization therapy
HonorHealth becomes the first in Arizona and the Southwest to offer the new WiSE® leadless cardiac therapy for patients with advanced heart failure. SCOTTSDALE, AZ, UNITED STATES, September 22, 2025 /EINPresswire.com/ -- HonorHealth, a leading Valley …
APA Statement on White House Announcement on Autism
Washington, D.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- In reaction to today’s White House announcement, the American Psychiatric Association issued the following statement: “It is essential that the administration prioritizes evidence-based support for …
Ergodyne Debuts Full Brim Type 2 Helmets Blending Familiar Style, Airy Comfort and Expanded Safety
St. Paul, MN, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Ergodyne announced the release of its latest Type 2 Safety Helmets designed to overcome worker resistance to change by combining the familiar look of a full brim hard hat with the expanded protection of Type …
AMN Healthcare Announces Pricing of Senior Notes Offering
DALLAS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), announced today that its wholly owned subsidiary, AMN Healthcare, Inc., priced its previously announced private offering of $400.0 million aggregate principal amount of …
Fortrea Appoints William Sharbaugh to Board of Directors
DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company’s Board of Directors. Mr. Sharbaugh brings …
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell …
BetaGlue Therapeutics gibt die Ernennung von Alexis Peyroles zum neuen Chief Executive Officer bekannt
MAILAND, Sept. 22, 2025 (GLOBE NEWSWIRE) -- BetaGlue® Therapeutics (im Folgenden „BetaGlue“ oder „das Unternehmen“), ein auf Onkologie spezialisiertes Unternehmen, das die innovative Radiotherapie-Plattform YntraDose® für die gezielte und personalisierte …
BetaGlue Therapeutics annonce la nomination d’Alexis Peyroles au poste de directeur général
MILAN, 22 sept. 2025 (GLOBE NEWSWIRE) -- BetaGlue® Therapeutics (« BetaGlue » ou la « Société »), une entreprise d’oncologie en phase clinique développant une plateforme innovante de radiothérapie pour le traitement ciblé et personnalisé des tumeurs …
MBX Biosciences Announces Proposed Public Offering
CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic …
GENFIT : Résultats financiers du premier semestre 2025 et point sur les activités de la Société
Trésorerie et équivalents de trésorerie s’élevant à 107,5 millions d’euros au 30 juin 2025 n’incluant pas le paiement d’étape de 26,5 millions d’euros facturé en mai 2025 (reçu en juillet 2025) à la suite de l'approbation par trois pays européens majeurs …
GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update
Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in July 2025) upon pricing and reimbursement approval of Iqirvo® (elafibranor) in three major European countries €33. …
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 HAYWARD, Calif., Sept. 22, 2025 (GLOBE …
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced …
J-Star Holding Names Sam Van as Chief Executive Officer
TAICHUNG CITY, Taiwan, Sept. 22, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications including personal …
Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform
MOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance …
Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares
VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to …
Until Labs Announces $58M Series A Funding Round, to Develop an Organ Cryopreservation Product for Transplant Patients and Surgeons
SAN FRANCISCO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Until Labs announced today a Series A funding round of $58 million, led by Founders Fund with participation from Lux Capital and Field Ventures. The company develops perfusion hardware, cryoprotective …
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback …
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination
Semnur’s shares of common stock and warrants are expected to continue to trade on the OTC Markets under the ticker symbols “SMNR” and “SMNRW”, respectively. Scilex (together with its affiliates) owns approximately 87.5% of Semnur common stock post Business …